Zhaoting Meng
Overview
Explore the profile of Zhaoting Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
74
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weng S, Meng Z, Li L, Li J, Fan X, Zhang Z, et al.
CNS Neurosci Ther
. 2024 Nov;
30(11):e70112.
PMID: 39533403
Background: Supplementary motor area (SMA) syndrome commonly occurs after glioma resection and requires weeks to months of recovery. Methods: Thirty-four glioma patients with SMA syndrome were reviewed and assigned to...
2.
Zhang L, Meng Z, Huang C, Xian J
Eur J Radiol
. 2024 Jan;
172:111326.
PMID: 38280301
Purpose: To investigate whether the quantitative multiparameters of F-FDG PET/MRI can predict expression of epidermal growth factor receptor (EGFR) of hypopharyngeal squamous cell carcinoma (HSCC). Methods: Twenty-one patients with HSCC...
3.
Peng L, Liao Y, Zhou R, Zhong Y, Jiang H, Wang J, et al.
Eur J Nucl Med Mol Imaging
. 2023 Aug;
50(12):3796.
PMID: 37610433
No abstract available.
4.
Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z, et al.
Mol Cancer
. 2023 Aug;
22(1):124.
PMID: 37543587
Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as...
5.
Peng L, Liao Y, Zhou R, Zhong Y, Jiang H, Wang J, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jul;
50(12):3723-3734.
PMID: 37401938
Purpose: PET/MRI has become an important medical imaging approach in clinical practice. In this study, we retrospectively investigated the detectability of fluorine-18 (F)-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ([F]FDG PET/MRI)...
6.
Huang C, Zhang L, Meng Z, Song T, Mukherji S, Chen X, et al.
J Comput Assist Tomogr
. 2022 Nov;
46(6):968-977.
PMID: 36399537
Objective: The aim of the study is to investigate the value of pretreatment integrated positron emission tomography/magnetic resonance imaging (PET/MRI) in predicting the prognosis of patients with hypopharyngeal squamous cell...
7.
Meng Z, Zhang L, Huang C, Piao Y, Chen X, Xian J
Neuroradiology
. 2022 Sep;
64(11):2153-2162.
PMID: 36121469
Purpose: Among head and neck cancers, hypopharyngeal squamous cell carcinoma (HSCC) shows the highest malignancy, which is associated with histologic grading. This study was designed to investigate whether quantitative parameters...
8.
Meng Z, Zhang C, Zuo R, Zhu F, Wang Y, Mi R, et al.
Anticancer Drugs
. 2022 Mar;
33(7):682-685.
PMID: 35324532
Selpercatinib has been approved by most major regulatory bodies in 2020 and become the standard therapy for rearranged during transfection ( RET )-rearranged nonsmall-cell lung cancer (NSCLC). Knowledge is limited...
9.
Zhang C, Wang J, Wang X, Meng Z, Cheng Y, Li K
Cancer Biol Med
. 2021 Jul;
19(8).
PMID: 34302324
Objective: In the phase II ALTER-1202 (NCT03059797) trial, anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced small-cell lung cancer (SCLC) who underwent at least...
10.
Wang J, Sun T, Meng Z, Wang L, Li M, Chen J, et al.
Cancer Lett
. 2021 Jan;
503:197-212.
PMID: 33493586
Patient mortality rates have remained stubbornly high for the past decades in small cell lung cancer (SCLC) because of having no standard targeted therapies with confirmed advantages at present. Poly...